Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The honest answer is that it depends on the indication, and the timeline varies enough between tissue types that a single number is misleading
A thorough explanation outlining why you think the treatment should be covered, citing any pertinent health conditions
Blood glucose should be closely monitored
Lilly's first Phase 3 readout (TRIUMPH4) reported strong results in people with obesity/overweight and knee osteoarthritis, including: ~28.7% average weight loss at 68 weeks at the 12 mg dose (topline reporting), plus improvements in pain and function measures The important phrase there is "topline"
US$ 27.21
US$ 26.55
US$ 26.53
US$ 24.01
US$ 22.55
